Cargando…
523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
BACKGROUND: Nirmatrelvir/ritonavir (n/r) is a currently 1 of 2 oral medications FDA-approved for treatment of COVID-19 in patients ≥ 12 years of age AND ≥ 40 kg. To date, dosing recommendations for adolescents are extrapolated primarily from adult studies. We conducted a retrospective study at a lar...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Oxford University Press
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677984/ http://dx.doi.org/10.1093/ofid/ofad500.592 |